June 2022 FDA Recall Testosterone Cypionate by Sun Pharmaceutical Industries Inc
D-1153-2022 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on June 3, 2022 for the product Testosterone Cypionate. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1153-2022

Reason for Recall
CGMP Deviations: lots made with same active pharmaceutical ingredient (API) as lots that were rejected due to manufacturing issues that could cause the product to be out of specification for impurities.
Initiated
06-03-2022
Reported
06-29-2022
Quantity
97,450 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Nationwide in the USA and Puerto Rico
Testosterone Cypionate Injection, USP, 200 mg/mL, 1 mL Single-dose vial per carton, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 62756-015-40.

Batch or Lot Expiration Information

Lot# HAC1974A, HAC1978A, Exp 06/2023